GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Consensus Rating of “Buy” from Analysts

GeoVax Labs, Inc. (NASDAQ:GOVX) has earned a consensus rating of “Buy” from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $14.20.

A number of equities research analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of GeoVax Labs in a research note on Friday, November 15th. D. Boral Capital reaffirmed a “buy” rating and set a $18.00 price objective on shares of GeoVax Labs in a research note on Friday, January 31st. Finally, Alliance Global Partners assumed coverage on shares of GeoVax Labs in a research note on Monday, November 11th. They set a “buy” rating and a $15.00 price objective on the stock.

Institutional Investors Weigh In On GeoVax Labs

A number of institutional investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC acquired a new stake in GeoVax Labs in the 4th quarter valued at $104,000. Northern Trust Corp acquired a new stake in GeoVax Labs in the 4th quarter valued at $29,000. Geode Capital Management LLC grew its stake in GeoVax Labs by 59.0% in the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after acquiring an additional 33,440 shares during the period. Finally, Virtu Financial LLC acquired a new stake in GeoVax Labs in the 3rd quarter valued at $97,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Trading Down 3.9 %

Shares of NASDAQ:GOVX opened at $1.47 on Wednesday. GeoVax Labs has a twelve month low of $1.09 and a twelve month high of $11.18. The company’s 50 day moving average is $2.05 and its 200 day moving average is $2.66.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.